Trial Profile
Long-Term Immunologic Follow-Up of Women Who Received One, Two, and Three Doses of the Bivalent HPV Vaccine in the Costa Rica HPV-16/18 Vaccine Trial (CVT): Generating Durability Data: The ESCUDDO-CVT Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms The ESCUDDO-CVT Study
- 25 Feb 2023 Planned number of patients changed from 900 to 991.
- 08 Feb 2023 Planned End Date changed from 31 Dec 2022 to 28 Feb 2026.
- 08 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 28 Feb 2026.